Prince Pharmaceutical Co., Ltd. (TPEX:6935)
Taiwan · Delayed Price · Currency is TWD 30.70
+0.10 (0.33%)
Jan 22, 2026, 9:58 AM CST
Prince Pharmaceutical Revenue
Prince Pharmaceutical had revenue of 448.06M TWD in the half year ending June 30, 2025, with 25.86% growth. This brings the company's revenue in the last twelve months to 798.27M, up 8.29% year-over-year. In the year 2024, Prince Pharmaceutical had annual revenue of 690.03M, down -8.40%.
Revenue (ttm)
798.27M
Revenue Growth
+8.29%
P/S Ratio
1.40
Revenue / Employee
3.80M
Employees
210
Market Cap
1.12B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 690.03M | -63.30M | -8.40% |
| Dec 31, 2023 | 753.33M | 40.80M | 5.73% |
| Dec 31, 2022 | 712.53M | 271.45M | 61.54% |
| Dec 31, 2021 | 441.08M | 145.28M | 49.12% |
| Dec 31, 2020 | 295.79M | 46.19M | 18.50% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bora Pharmaceuticals Co., LTD. | 21.10B |
| Lotus Pharmaceutical | 18.66B |
| PharmaEssentia | 13.82B |
| Center Laboratories | 1.57B |
| Oneness Biotech | 117.33M |
| Polaris Group | 70.83M |
| Lumosa Therapeutics | 42.59M |
| Caliway Biopharmaceuticals | 34.99M |